Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.42 |
| ▸ | SCN5A | Q14524 | 6/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.37 |
| ▸ | SCN1A | P35498 | 1/20 | 0.37 |
| ▸ | SCN2A | Q99250 | 1/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.37 |
| ▸ | LMNA | P02545 | 1/20 | 0.37 |
| ▸ | PSD | A5PKW4 | 1/20 | 0.36 |
| ▸ | RIPK3 | Q9Y572 | 1/20 | 0.35 |
| ▸ | BRD4 | O60885 | 2/20 | 0.35 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.34 |
| ▸ | PTGER4 | P35408 | 1/20 | 0.34 |
| ▸ | MAOA | P21397 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22314918 | 0.84 | SCN5A (0.52) | SCN5ASCN1ASCN2APSDGRIN2B | |
| SCHEMBL22314912 | 0.84 | SCN5A (0.52) | NPSR1SCN5ASCN1ASCN2APSD | |
| SCHEMBL22314914 | 0.83 | SCN5A (0.40) | SCN5ASCN1ASCN2APSDRIPK3 | |
| SCHEMBL22314209 | 0.83 | SCN5A (0.42) | NPSR1SCN5AALDH1A1SCN1ASCN2A | |
| SCHEMBL22314925 | 0.83 | SCN5A (0.40) | SCN5ASCN1ASCN2APSDGRIN2B | |
| SCHEMBL25865160 | 0.82 | SCN5A (0.41) | SCN5AALDH1A1SCN1ASCN2AKDM4E | |
| SCHEMBL22314514 | 0.82 | SCN5A (0.45) | SCN5APSDGRIN2B | |
| SCHEMBL22314926 | 0.81 | SCN5A (0.40) | SCN5ASCN1ASCN2APSDGRIN2B | |
| SCHEMBL22314208 | 0.81 | SCN5A (0.41) | SCN5ASCN1ASCN2APSDBRD4 | |
| SCHEMBL25865032 | 0.81 | SCN5A (0.44) | SCN5APSDGRIN2BMAOA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230219938-A1 | COMPOUNDS AND THEIR METHODS OF USE | PRAXIS PREC MEDICINES INC (US) | 2023-07-13 | — | — | US | disclosed |
| US-20230219938-A1 | COMPOUNDS AND THEIR METHODS OF USE | PRAXIS PREC MEDICINES INC (US) | 2023-07-13 | — | — | US | disclosed |
| US-20200247793-A1 | COMPOUNDS AND THEIR METHODS OF USE | PRAXIS PRECISION MEDICINES, INC. (US) | 2020-08-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200247793-A1 | COMPOUNDS AND THEIR METHODS OF USE | SCN1A, SCN3A, SCN1B | NPSR1 1382/4885SCN5A 8/4885ALDH1A1 916/4885 |
| US-20230219938-A1 | COMPOUNDS AND THEIR METHODS OF USE | SCN1A, SCN3A, SCN1B | NPSR1 1382/4885SCN5A 8/4885ALDH1A1 916/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.